The FDA approves BrainSense Adaptive deep brain stimulation and electrode identifier technology for the treatment of ...
The company's adaptive deep brain stimulation technology for Parkinson's disease therapy is expected to be available ...
The FDA has approved BrainSense, an adaptive deep brain stimulation system that can adjust therapy for Parkinson’s disease in ...
2don MSN
After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive ...
Medtronic (NYSE:MDT) has won FDA approval for a deep brain stimulation system for Parkinson’s disease. The approval is for ...
(NYSE: MDT) announced today that the FDA approved its BrainSense adaptive deep brain stimulation (aDBS) platform.
The closed-loop system dynamically self-adjusts DBS therapy to individual brain activity in real time, providing personalized ...
For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:MDT), a global ...
Medtronic (MDT) announced FDA approval of BrainSense Adaptive deep brain stimulation – aDBS – and BrainSense Electrode Identifier. There is no cure for debilitating neurological conditions like ...
The BrainSense adaptive deep brain stimulation system personalizes therapy by dynamically adjusting stimulation based on real ...
Shortly after obtaining a greenlight in Europe and after more than 10 years in development, Medtronic has now received the ...
BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) for patients with Parkinson’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results